AWY
~{N}-[2-(7-methoxynaphthalen-1-yl)ethyl]ethanamide
Find entries where: AWY
is present as a standalone ligand in 2 entries
Chemical Component Summary | |
---|---|
Name | ~{N}-[2-(7-methoxynaphthalen-1-yl)ethyl]ethanamide |
Identifiers | ~{N}-[2-(7-methoxynaphthalen-1-yl)ethyl]ethanamide |
Formula | C15 H17 N O2 |
Molecular Weight | 243.301 |
Type | NON-POLYMER |
Isomeric SMILES | CC(=O)NCCc1cccc2c1cc(cc2)OC |
InChI | InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17) |
InChIKey | YJYPHIXNFHFHND-UHFFFAOYSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 35 |
Chiral Atom Count | 0 |
Bond Count | 36 |
Aromatic Bond Count | 11 |
Drug Info: DrugBank
DrugBank ID | DB06594 |
---|---|
Name | Agomelatine |
Groups |
|
Description | Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. The Committee for Medical Products for Human Use (CHMP) recommended refusal of marketing authorization on 27 July 2006. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name. |
Synonyms |
|
Brand Names |
|
Indication | Agomelatine is indicated to treat major depressive episodes in adults. |
Categories |
|
ATC-Code | N06AX22 |
CAS number | 138112-76-2 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
5-hydroxytryptamine receptor 2C | MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPD... | unknown | antagonist |
Melatonin receptor type 1A | MQGNGSALPNASQPVLRGDGARPSWLASALACVLIFTIVVDILGNLLVIL... | unknown | agonist |
Melatonin receptor type 1B | MSENGSFANCCEAGGWAVRPGWSGAGSARPSRTPRPPWVAPALSAVLIVT... | unknown | agonist |
Cytochrome P450 1A2 | MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL... | unknown | substrate |
Cytochrome P450 2C9 | MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI... | unknown | inhibitor |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL10878 |
PubChem | 82148 |
ChEMBL | CHEMBL10878 |
ChEBI | CHEBI:134990 |
CCDC/CSD | KAXSEJ, FAFGOL01, KAXSIN, OTAQIK, FAFGOL, WERNOW03, OTAQEG, KAXSOT, FAFGOL02, FAFGOL03, FAFGUR, WERNOW, KAXSUZ, FAFHEC, WERNOW02, WERNOW01, WERNOW04 |
COD | 4505886, 4505887, 4500184, 4505888, 2108512, 2108513, 2009809, 4505889, 4500185 |